GlassScriptPhysician profile
Jonathan G Welden
NPI 1194935635
$24,263.80
in general payments reported to CMS, 2019-2025
14 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,526 · 2021: $1,642 · 2022: $257 · 2023: $627 · 2024: $606 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Consulting Fee: $580 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.98 |
| Consulting Fee | $580.00 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22,346.41 | 2019-2022 | |
| Novo Nordisk INC | $742.71 | 2022-2025 | Ozempic, Rybelsus |
| Beta Bionics, INC. | $345.63 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $235.43 | 2022-2024 | Evenity |
| Sequel Med Tech, LLC | $153.92 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $138.64 | 2024-2025 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $118.62 | 2025 | |
| Ascensia Diabetes Care US INC. | $43.51 | 2025 | |
| Abbvie INC. | $39.99 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Abbott Laboratories | $23.87 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $20.34 | 2025 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $17.19 | 2021 | |
| Medtronic Minimed, INC. | $13.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Welden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.